Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5742031 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SLC7A5 | |
| SCHEMBL5743803 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SLC7A5 | |
| SCHEMBL5742035 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SLC7A5 | |
| SCHEMBL5743977 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SLC7A5 | |
| SCHEMBL5743976 | 1.00 | ALDH1A1 (0.38) | ALDH1A1SLC7A5 | |
| SCHEMBL3267512 | 0.79 | — | — | |
| SCHEMBL3267513 | 0.79 | — | — | |
| SCHEMBL5252475 | 0.74 | — | — | |
| SCHEMBL29574183 | 0.72 | — | — | |
| SCHEMBL15834914 | 0.70 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | ALDH1A1 3118/4885SLC7A5 1328/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | ALDH1A1 3111/4885SLC7A5 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.